Exhibit 99.1

DJO Investor/Media Contact:

DJO Global, Inc.

Matt Simons

SVP Business Development and Investor Relations

760.734.5548

matt.simons@DJOglobal.com

FOR IMMEDIATE RELEASE

DJO GLOBAL ANNOUNCES FINANCIAL RESULTS FOR THIRD QUARTER OF 2013

Revenue growth continues to accelerate

SAN DIEGO, CA, OCTOBER 29, 2013 – DJO Global, Inc. (“DJO” or the “Company”), a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its public reporting subsidiary, DJO Finance LLC (“DJOFL”), for the third quarter ended September 28, 2013.

Third Quarter Results

DJOFL achieved net sales for the third quarter of 2013 of $288.0 million, reflecting growth of 5.1 percent, compared with net sales of $274.0 million for the third quarter of 2012. Net sales for the third quarter of 2013 were favorably impacted by $1.2 million related to changes in foreign currency exchange rates compared to the rates in effect in the third quarter of 2012. Excluding the impact of changes in foreign currency exchange rates from rates in effect in the prior year period (“constant currency”), net sales for the third quarter of 2013 increased 4.7 percent compared to net sales for the third quarter of 2012. The third quarters of 2013 and 2012 each had 63 shipping days.

For the third quarter of 2013, DJOFL reported a net loss attributable to DJOFL of $18.5 million, compared to a net loss of $22.6 million for the third quarter of 2012. The reduction in the net loss was due primarily to the contribution from increased revenue and reduced interest expense. As detailed in the attached financial tables, the results for the current and prior year third quarter periods were impacted by significant non-cash items, non-recurring items and other adjustments.

-more-

The Company defines Adjusted EBITDA as net (loss) income attributable to DJOFL plus interest expense, net, income tax provision (benefit), and depreciation and amortization, further adjusted for certain non-cash items, non-recurring items and other adjustment items as permitted in calculating covenant compliance under the Company’s amended senior secured credit facility and the indentures governing its 8.75% second priority senior secured notes, its 9.875% and 7.75% senior notes and its 9.75% senior subordinated notes. Reconciliation between net loss and Adjusted EBITDA is included in the attached financial tables.

Adjusted EBITDA for the third quarter of 2013 was $63.7 million, or 22.1 percent of net sales, reflecting a decrease of 1.9 percent compared with Adjusted EBITDA of $64.9 million, or 23.7 percent of net sales, for the third quarter of 2012.

For the twelve months ended September 28, 2013 (LTM), Adjusted EBITDA was $262.1 million, or 22.7 percent of LTM net sales of $1,152.4 million, including pre-acquisition Adjusted EBITDA and expected future cost savings aggregating $0.3 million related to the Company’s recent acquisition of Exos Corporation.

“It is terrific to see our team continue to deliver strong accelerating sales growth in the third quarter with approximately five percent growth in net sales on a constant currency basis compared to the third quarter of 2012. Our successful new product launches and strong global commercial execution continue to drive momentum across most of our businesses.” said Mike Mogul, DJO’s president and chief executive officer. “I want to especially congratulate our Bracing & Vascular, Surgical Implant and International teams, for delivering strong constant currency growth in the third quarter of 2013 of 8.0%, 16.4% and 7.0%, respectively, as compared to the prior year period. Our Recovery Sciences business continues to be impacted by Medicare’s 2012 non-coverage decision related to Transcutaneous Electrical Nerve Stimulation (“TENS”) for chronic low back pain (“CLBP”) and slow market conditions for capital equipment purchasing, which is impacting our Chattanooga business. Excluding Recovery Sciences, aggregate net sales from our other business segments for the third quarter of 2013 increased by 8.5% compared to the prior year period.

-more-

“For the third quarter, Adjusted EBITDA contracted from the prior year amounts, due primarily to the lost contribution margin from declining revenues in our Recovery Sciences segment, partly to the impact of the medical device excise tax, which became effective January 1, 2013, and partly to increased operating expense investments related to new product development and other revenue growth initiatives. Excluding Recovery Sciences, Adjusted EBITDA for the third quarter of 2013 increased by 4.0% compared to Adjusted EBITDA for the third quarter of 2012.

“We continue to be very pleased with the revenue growth contributed by our recent new product launches and other commercial initiatives. These successful growth initiatives have enabled our Bracing and Vascular, International and Surgical Implant segments to achieve growth rates that we believe are market leading. We remain diligently focused on improving the sales results of our Recovery Sciences segment. We believe that the impact of recent and upcoming product launches, combined with having reached the anniversary date of Medicare’s noncoverage decision for TENS for CLBP late in the third quarter of 2013, will improve the future sales results for this segment. This improvement, combined with continued strong performance from our other segments should permit us to report stronger revenue results and higher total company growth rates in future quarters, which in turn should improve our Adjusted EBITDA results.

“On a somber note, we suffered a fire in our Tunisia manufacturing facility late in the quarter. Thankfully, no one was injured in the fire, but our production capacity in Tunisia has been temporarily reduced. Given our operational contingency plans, the finished goods inventory on hand at our other distribution locations and our insurance coverage, we do not currently believe that the fire will have a material impact on our results of operations or ability to service our customers. However, we may see revenue disruption in our international markets in the fourth quarter, which we currently estimate could be up to $5 million.”

Sales by Business Segment

In the first quarter of 2013, DJOFL reassigned certain product lines between its Bracing and Vascular and Recovery Sciences segments and revised the way it allocates costs among its segments. Segment information for all periods presented has been restated to reflect these changes.

-more-

Net sales for DJO’s Bracing and Vascular segment were $120.9 million in the third quarter of 2013, reflecting growth of 8.0%, compared to the third quarter of 2012, driven by strong contribution from the sales of new products and improving sales execution.

Net sales for DJO’s Recovery Sciences segment were $76.7 million in the third quarter of 2013, reflecting a contraction of 4.4%, compared to the third quarter of 2012, primarily due to the effects of the Medicare CLBP decision on the EMPI business unit and slow market conditions for capital equipment sold by the Chattanooga business unit. The third quarter sales results for the Recovery Sciences segment reflected strong sequential improvement from the second quarter of 2013, which reflected a contraction of 8.1% from the prior year second quarter period.

Third quarter net sales within the International segment were $70.4 million, reflecting an increase in constant currency of 7.0% from the prior year period, excluding the impact of $1.2 million of favorable changes in foreign currency exchange rates from rates in effect in the third quarter of 2012. The strong international growth is being driven by increased penetration in certain geographies and the positive impact of sales of new products.

Net sales for the Surgical Implant segment were $20.0 million for the third quarter of 2013, reflecting an increase of 16.4% over net sales in the third quarter of 2012, driven by strong sales of each of the Company’s shoulder, knee and hip product lines.

As of September 28, 2013, the Company had cash balances of $33.5 million and available liquidity of $99.5 million under its $100 million revolving line of credit.

Year-to-Date Results

DJOFL achieved net sales of $861.9 million for the nine months ended September 28, 2013, reflecting growth of 2.7 percent compared to net sales of $838.9 million for the nine months ended September 29, 2012. Net sales for the first nine months of 2013 were favorably impacted by changes in foreign currency exchange rates aggregating $1.9 million compared to the rates in effect in the first nine months of 2012. In constant currency, net sales for the first nine months of 2013 increased by 2.5 percent compared to net sales for the first nine months of 2012. The nine months ended September 28, 2013

-more-

included 190 shipping days, one fewer than the nine months ended September 29, 2012. Excluding Recovery Sciences, aggregate net sales from our other business segments for the nine months ended September 28, 2013, increased by 6.7% compared to net sales for the nine months ended September 29, 2012.

For the first nine months of 2013, DJOFL reported a net loss attributable to DJOFL of $71.7 million, compared to a net loss attributable to DJOFL of $72.1 million for the first nine months of 2012. As detailed in the attached financial tables, the results for the current and prior year nine month periods were impacted by significant non-cash items, non-recurring items and other adjustments.

Adjusted EBITDA for the first nine months of 2013 was $190.2 million, or 22.1 percent of net sales, compared to Adjusted EBITDA of $199.4 million, or 23.8 percent of net sales, for the first nine months of 2012. Excluding Recovery Sciences, Adjusted EBITDA for the for the nine months ended September 28, 2013, increased by 1.0% compared to Adjusted EBITDA for the nine months ended September 29, 2012.

Conference Call Information

DJO has scheduled a conference call to discuss this announcement beginning at 1:00 pm, Eastern Time today, October 29, 2013. Individuals interested in listening to the conference call may do so by dialing (866) 394-8509 (International callers please use (706) 643-6833), using the reservation code 22322226. A telephone replay will be available for 48 hours following the conclusion of the call by dialing (855) 859-2056 and using the above reservation code. The live conference call and replay will be available via the Internet at www.DJOglobal.com.

About DJO Global

DJO Global is a leading global developer, manufacturer and distributor of high-quality medical devices that provide solutions for musculoskeletal health, vascular health and pain management. The Company’s products address the continuum of patient care from injury prevention to rehabilitation after surgery, injury or from degenerative disease, enabling people to regain or maintain their natural motion. Its products are used by orthopedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers and other healthcare professionals. In addition, many of the Company’s medical devices and related accessories are used by athletes and patients for injury prevention and at-home physical therapy treatment. The

-more-

Company’s product lines include rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management and physical therapy products. The Company’s surgical division offers a comprehensive suite of reconstructive joint products for the hip, knee and shoulder. DJO Global’s products are marketed under a portfolio of brands including Aircast^®, Chattanooga, CMF™, Compex^®, DonJoy^®, Empi^®, ProCare^®, DJO^® Surgical, Dr. Comfort^® and Exos^TM. For additional information on the Company, please visit www.DJOglobal.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements relate to, among other things, the Company’s expectations for its growth in revenue and Adjusted EBITDA and its opportunities to improve commercial execution and to develop new products and services. The words “believe,” “will,” “should,” “expect,” “target,” “intend,” “estimate” and “anticipate,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based on the Company’s current expectations and are subject to a number of risks, uncertainties and assumptions, many of which are beyond the Company’s ability to control or predict. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the successful execution of the Company’s business strategies relative to its Bracing and Vascular, Recovery Sciences, International and Surgical Implant segments; the continued growth of the markets the Company addresses and any impact on these markets from changes in global economic conditions; the successful execution of the Company’s acquisition strategies; the impact of potential reductions in reimbursement levels and coverage by Medicare and other governmental and commercial payors; the Company’s highly leveraged financial position; the Company’s ability to successfully develop, license or acquire, and timely introduce and market new products or product enhancements; risks relating to the Company’s international operations; resources needed and risks involved in complying with government regulations; the availability and sufficiency of insurance coverage for pending and future product liability claims,

-more-

including multiple lawsuits related to the Company’s cold therapy products and its discontinued pain pump business; and the effects of healthcare reform, Medicare competitive bidding, managed care and buying groups on the prices of the Company’s products. These and other risk factors related to DJO are detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission on February 28, 2013. Many of the factors that will determine the outcome of the subject matter of this press release are beyond the Company’s ability to control or predict.

-tables to follow-

DJO Finance LLC

Unaudited Condensed Consolidated Statements of Operations

(In thousands)

Note 1 — Cost of sales is exclusive of amortization of intangible assets of $8,809 and $26,368 for the three and nine months ended September 28, 2013 and $9,837 and $29,513 for the three and nine months ended September 29, 2012, respectively.

-more-

DJO Finance LLC

Unaudited Condensed Consolidated Balance Sheets

(In thousands)

-more-

DJO Finance LLC

Unaudited Segment Information

(In thousands)

In the first quarter of 2013, DJOFL reassigned certain product lines between its Bracing and Vascular and Recovery Sciences segments and revised the way it allocates costs among its segments. Segment information for all periods presented has been restated to reflect these changes.

-more-

DJO Finance LLC

Adjusted EBITDA

For the Three and Nine Months Ended September 28, 2013 and September 29, 2012

(unaudited)

Our Amended Senior Secured Credit Facility, consisting of a $857.7 million term loan and a $100.0 million revolving credit facility, under which the outstanding balance was zero as of September 28, 2013, and the Indentures governing our $330.0 million of 8.75% second priority senior secured notes, $440.0 million of 9.875% senior notes, $300.0 million of 7.75% senior notes, and $300.0 million of 9.75% senior subordinated notes represent significant components of our capital structure. Under our Amended Senior Secured Credit Facility, we are required to maintain a specified first lien net leverage ratio, which is determined based on our Adjusted EBITDA. If we fail to comply with the first lien net leverage ratio under our Amended Senior Secured Credit Facility, we would be in default. Upon the occurrence of an event of default under the Amended Senior Secured Credit Facility, the lenders could elect to declare all amounts outstanding under the Amended Senior Secured Credit Facility to be immediately due and payable and terminate all commitments to extend further credit. If we were unable to repay those amounts, the lenders under the Amended Senior Secured Credit Facility could proceed against the collateral granted to them to secure that indebtedness. We have pledged a significant portion of our assets as collateral under the Amended Senior Secured Credit Facility. Any acceleration under the Amended Senior Secured Credit Facility would also result in a default under the Indentures governing the notes, which could lead to the note holders electing to declare the principal, premium, if any, and interest on the then outstanding notes immediately due and payable. In addition, under the Indentures governing the notes, our ability to engage in activities such as incurring additional indebtedness, making investments, refinancing subordinated indebtedness, paying dividends and entering into certain merger transactions is governed, in part, by our ability to satisfy tests based on Adjusted EBITDA. Our ability to meet the covenants specified above will depend on future events, many of which are beyond our control, and we cannot assure you that we will meet those covenants.

Adjusted EBITDA is defined as net income (loss) attributable to DJO Finance LLC plus interest expense, net, income tax provision (benefit), and depreciation and amortization, further adjusted for certain non-cash items, non-recurring items and other adjustment items as permitted in calculating covenant compliance and other ratios under our Amended Senior Secured Credit Facility and the Indentures governing our 8.75% second priority senior secured notes, 9.875% senior notes, 7.75% senior notes and our 9.75% senior subordinated notes. We believe that the presentation of Adjusted EBITDA is appropriate to provide additional information to investors about the calculation of, and compliance with, certain financial covenants and other ratios in our Amended Senior Secured Credit Facility and the Indentures. Adjusted EBITDA is a material component of these calculations.

Adjusted EBITDA should not be considered as an alternative to net income (loss) or other performance measures presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”), or as an alternative to cash flow from operations as a measure of our liquidity. Adjusted EBITDA does not represent net income (loss) or cash flow from operations as those terms are defined by GAAP and does not necessarily indicate whether cash flows will be sufficient to fund cash needs. In particular, the definition of Adjusted EBITDA under our Amended Senior Secured Credit Facility and the Indentures allows us to add back certain non-cash, extraordinary, unusual or non-recurring charges that are deducted in calculating net income (loss). However, these are expenses that may recur, vary greatly and are difficult to predict. While Adjusted EBITDA and similar measures are frequently used as measures of operations and the ability to meet debt service requirements, Adjusted EBITDA is not necessarily comparable to other similarly titled captions of other companies due to the potential inconsistencies in the method of calculation.

-more-

The following table provides reconciliation between net loss and Adjusted EBITDA:

-more-

-more-

###